A groundbreaking medical study has revealed that an “immune fog” gradually clouds the body’s defenses years before a tumor develops, offering a brand-new approach to lung cancer interception. Researchers at University College London (UCL) discovered that specialized immune cells build up quietly inside the body long before malignant growths appear, a finding that could pave the way for early detection blood tests and targeted preventative treatments.
The study, led by Associate Professor James Reading and Professor Sam Janes alongside a multidisciplinary team, was published in the journal Nature. By analyzing blood and tissue samples collected from long-running lung cancer surveillance and screening programs—as well as studying similar biological processes in mice—the investigators mapped out how precancerous lesions evolve into full-fledged tumors.
Tracking the Immune System Shift
The research team found that regulatory T cells (Tregs), a specialized subset of immune cells, progressively accumulate months or years before cancer takes hold. This growing accumulation creates what scientists describe as an immune fog, which impairs the body’s natural ability to detect and destroy emerging abnormal cells.
During early pulmonary tumorigenesis, a clonally integrated effector regulatory T cell (eTreg) network forms across draining lymph nodes, the bloodstream, and preinvasive lesions in the airways. According to the study’s authors, this discovery provides three major tools for clinical intervention:
- A diagnostic signature: A blood-based eTreg signature tracks preinvasive progression and peaks in individuals harboring high-risk lesions, helping clinicians identify patients with urgent clinical needs.
- An actionable target: The early eTreg network acts as a clear biological target for therapeutic intervention before invasion occurs.
- A potential drug strategy: Researchers demonstrated that PI3K-delta inhibition can dismantle the preinvasive eTreg circuit, offering a way to intercept lung cancer using medications with favorable safety and targeting profiles.
Implications for High-Risk Patients
Lung cancer remains one of the most challenging malignancies to treat successfully, largely because it is frequently diagnosed at an advanced stage. By focusing on preinvasive lesions—such as bronchial changes monitored in high-risk groups like heavy smokers—this research shifts the medical paradigm from late-stage treatment to early interception.
The findings draw upon major ongoing initiatives, including the UCLH bronchoscopy surveillance study, the ASCENT study funded by Cancer Research UK, and the SUMMIT study funded by GRAIL. By combining data from these extensive trials, the research team was able to pinpoint the molecular, histological, and immunocytochemical changes associated with lesion progression.
Although further clinical validation is required before these prototype blood tests and preventative therapies become standard clinical practice, experts believe targeting the preinvasive regulatory T cell axis marks a major step forward in cancer prevention. Investigators noted that this newly uncovered immune axis may also extend to other types of pre-cancers, opening doors to broader preventative oncology strategies in the future.
